Table 1.
Relative down-regulation of genes involved in proliferative activity in ASCs, as determined by PCR array and real-time PCR
Genes involved in proliferative activity | |||||||||
---|---|---|---|---|---|---|---|---|---|
BMPR1A | CREBBP | RBL2 | FZD5 | FGFR1 | Notch 3 | IL6ST | GLI1 | ||
Fold-changes in gene expression (ASCs/non-ASCs)* | -12.8075 | -11.6383 | -11.3575 | -12.5726 | -14.0221 | -12.309 | -12.6345 | -12.9973 | |
Relative mRNA expression† | |||||||||
ASC 1 | 106.2 | 109.8 | 110.3 | 109.5 | 107.5 | 111.7 | 111.0 | 112.8 | |
ASC 2 | 101.4 | 106.9 | 111.2 | 111.9 | 104.7 | 107.0 | 106.1 | 109.1 | |
ASC 3 | 117.5 | 121.4 | 120.7 | 121.8 | 119.6 | 123.5 | 120.2 | 123.1 | |
ASC 4 | 98.9 | 103.9 | 102.8 | 106.6 | 101.9 | 104.0 | 103.3 | 107.2 | |
ASC 5 | 102.4 | 101.5 | 105.3 | 103.1 | 100.8 | 105.1 | 102.4 | 104.3 | |
ASC 6 | 125.7 | 128.9 | 110.9 | 131.7 | 125.7 | 124.7 | 124.5 | 128.9 | |
ASC 7 | 104.1 | 107.6 | 110.4 | 111.4 | 108.9 | 112.1 | 108.3 | 107.7 | |
Non ASC 1 | 125.8 | 125.1 | 128.7 | 128.3 | 125.2 | 129.6 | 128.4 | 131.5 | |
Non ASC 2 | 93.4 | 96.7 | 99.2 | 100.4 | 96.6 | 98.9 | 98.1 | 96.9 | |
Non ASC 3 | 125.6 | 134.2 | 127.9 | 132.0 | 130.4 | 131.6 | 128.2 | 133.0 | |
Non ASC 4 | 132.7 | 139.0 | 135.6 | 138.7 | 135.4 | 140.4 | 130.5 | 141.2 | |
Non ASC 5 | 106.0 | 111.4 | 108.7 | 112.6 | 109.2 | 110.8 | 115.0 | 113.8 | |
Non ASC 6 | 123.3 | 131.3 | 143.5 | 129.2 | 127.7 | 130.8 | 129.0 | 131.8 | |
Non ASC 7 | 122.1 | 127.5 | 126.6 | 129.1 | 124.1 | 121.9 | 126.2 | 129.4 | |
Average relative mRNA expression of ASCs | 108.0 | 111.4 | 110.2 | 113.7 | 109.8 | 112.6 | 110.8 | 113.3 | |
Average relative mRNA expression of non ASCs | 113.8 | 118.1 | 117.8 | 119.7 | 116.2 | 118.5 | 116.9 | 119.8 |
Abbreviations: BMPR1A Bone morphogenetic protein receptor, type IA, CREBBP CREB binding protein, RBL2 Retinoblastoma-like 2, FZD5 Frizzled family receptor 5, FGFR1 Fibroblast growth factor receptor 1, IL6ST Interleukin 6 signal transducer, GLI1 GLI family zinc finger 1.
*Fold-changes of down-regulated gene expression in ASCs relative to non-ASCs obtained from a representative AML patient.
†Relative mRNA expression was calculated as follows: 100 × threshold cycles of target/β-actin.